« Return to News | Study Conduct

Dropout rates for phase I oncology trials remain under 10%

Wednesday, September 4, 2013 12:04 PM

The overall dropout rate for oncology phase I trials is only 8%, according to a study by Cutting Edge Information. However, dropout rates tend to rise as the number of required visits increases.

The study, Phase I Clinical Trials: Optimizing Cost-Drivers for Clinical Pharmacology Programs, found the average number of patients enrolled for these trials across all therapeutic areas is 47.2.

Surveyed companies reported as few as 15 patients enrolled in their phase I trials. However, "one interviewed executive conducting a diabetes trial reported 200 enrolled patients, many more than any other trial," said Ryan McGuire, research team leader at Cutting Edge Information. "Though the diabetes trial had the highest patient enrollment, its total costs are 2.5 times less than the overall average. Patient recruitment was likely easy for this therapeutic area, and the trial required only four patient visits."

The next highest number of patients came from an oncology clinical trial. Initial patient enrollment ranged from 15 to 106, much higher than the average for phase I trials. Across other therapeutic areas, including cardiovascular, gastroenterology and women's health, average enrollment was generally between 20 and 40 patients.

The study reveals the average number of patients completing phase I trials by therapeutic area. Oncology trials align with the average dropout rate at 8%. Central nervous system/neurology trial results show a dropout rate at 7%. Women's health trials appear to have a high average dropout rate at 16%—double this study's overall average.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.